TPCW
AXSM icon

TD Private Client Wealth’s Axsome Therapeutics AXSM Stock Holding History

TD Private Client Wealth’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.59K Buy
+31
New +$6.72K ﹤0.01% 1164
2025
Q2 		– Sell
-14
Closed -$1.63K – 1417
2025
Q1 		$1.63K Buy
+14
New +$1.59K ﹤0.01% 1220

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TD Private Client Wealth's AXSM Position: Q2 2026 in Review

TD Private Client Wealth opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 31 shares worth $7.59K. The stake represents ﹤0.01% of the portfolio and ranks #1164 among its holdings. This is a return to the name: TD Private Client Wealth previously reported a position in AXSM as recently as Q1 2025.

TD Private Client Wealth first reported a position in AXSM in Q1 2025 and has held it in 2 quarters since. 505 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • TD Private Client Wealth held 31 shares of Axsome Therapeutics worth $7.59K as of Q2 2026.
  • Axsome Therapeutics was a new TD Private Client Wealth position in Q2 2026.
  • Axsome Therapeutics made up ﹤0.01% of TD Private Client Wealth's portfolio in Q2 2026, its #1164 holding.
  • TD Private Client Wealth first reported a position in Axsome Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • 505 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on TD Private Client Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.